[go: up one dir, main page]

ES2774190T3 - Composiciones de alfa-galactosidasa - Google Patents

Composiciones de alfa-galactosidasa Download PDF

Info

Publication number
ES2774190T3
ES2774190T3 ES17164713T ES17164713T ES2774190T3 ES 2774190 T3 ES2774190 T3 ES 2774190T3 ES 17164713 T ES17164713 T ES 17164713T ES 17164713 T ES17164713 T ES 17164713T ES 2774190 T3 ES2774190 T3 ES 2774190T3
Authority
ES
Spain
Prior art keywords
human
galactosidase
terminus
signal peptide
endoplasmic reticulum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17164713T
Other languages
English (en)
Inventor
Avidor Shulman
Uri Hanania
Tali Kizhner
Yoseph Shaaltiel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protalix Ltd
Original Assignee
Protalix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2011/000209 external-priority patent/WO2011107990A1/en
Application filed by Protalix Ltd filed Critical Protalix Ltd
Application granted granted Critical
Publication of ES2774190T3 publication Critical patent/ES2774190T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)

Abstract

Una proteína α-galactosidasa humana que comprende una glicina como el resto N-terminal en donde dicha proteína α-galactosidasa humana se fusiona traduccionalmente en el extremo C con un péptido señal de retención en el retículo endoplásmico y en donde la proteína α-galactosidasa humana se puede obtener expresando la proteína en una célula vegetal que comprende una construcción de ácido nucleico que comprende una secuencia de ácido nucleico que codifica una proteína α-galactosidasa humana fusionada traduccionalmente en el extremo N con un péptido señal de direccionamiento al retículo endoplásmico de ABPI de Arabidopsis y fusionada traduccionalmente en el extremo C con un péptido señal de retención en el retículo endoplásmico.
ES17164713T 2011-01-20 2011-09-07 Composiciones de alfa-galactosidasa Active ES2774190T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161434503P 2011-01-20 2011-01-20
US201161434499P 2011-01-20 2011-01-20
PCT/IL2011/000209 WO2011107990A1 (en) 2010-03-02 2011-03-02 Stabilized alpha-galactosidase and uses thereof

Publications (1)

Publication Number Publication Date
ES2774190T3 true ES2774190T3 (es) 2020-07-17

Family

ID=44786043

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17164713T Active ES2774190T3 (es) 2011-01-20 2011-09-07 Composiciones de alfa-galactosidasa

Country Status (20)

Country Link
US (1) US9732333B2 (es)
EP (2) EP3272861B1 (es)
JP (1) JP5913372B2 (es)
KR (1) KR101883803B1 (es)
CN (1) CN103443270B (es)
AU (1) AU2011356137A1 (es)
BR (1) BR112013018516B1 (es)
CA (1) CA2824791A1 (es)
CY (1) CY1122794T1 (es)
DK (2) DK2665814T3 (es)
ES (1) ES2774190T3 (es)
IL (1) IL227552B (es)
LT (2) LT3272861T (es)
LU (1) LUC00320I2 (es)
PL (1) PL3272861T3 (es)
PT (1) PT3272861T (es)
RS (1) RS60129B1 (es)
SI (1) SI3272861T1 (es)
SM (1) SMT202000201T1 (es)
WO (1) WO2012098537A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2696699A1 (en) 2007-08-20 2009-02-26 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
SMT202000201T1 (it) 2011-01-20 2020-05-08 Protalix Ltd Composizioni di alfa-galattosidasi
CA2902727C (en) * 2013-03-06 2020-08-18 Protalix Ltd. Use of plant cells expressing a tnfalpha polypeptide inhibitor in therapy
WO2014136114A1 (en) 2013-03-06 2014-09-12 Protalix Ltd. TNF alpha INHIBITOR POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME
TW202332774A (zh) * 2013-10-23 2023-08-16 美商健臻公司 重組醣蛋白及其用途
DK3271453T3 (da) 2015-03-17 2021-11-15 eleva GmbH Glycosylerede lysosomale proteiner, fremgangsmåde til fremstilling og anvendelser
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
KR20240042110A (ko) 2017-01-05 2024-04-01 프로탈릭스 리미티드 안정화된 알파-갈락토시다제를 이용하는 파브리의 치료를 위한 치료적 요법
IL257269A (en) * 2018-01-31 2018-04-09 Olender Tsviya Signaling is directed to the endoplasmic reticulum
KR102209198B1 (ko) * 2019-04-02 2021-02-02 주식회사 바이오앱 식물에서의 발현이 최적화된 재조합 이리신 유전자 및 이를 이용한 재조합 이리신 단백질의 생산 방법
KR102213745B1 (ko) 2019-04-16 2021-02-09 주식회사 바이오앱 돼지 유행성 설사병 바이러스 백신 조성물 및 이의 제조 방법
WO2020256372A1 (ko) 2019-06-17 2020-12-24 주식회사 바이오앱 아프리카 돼지열병의 진단을 위한 항원 생산용 재조합 벡터 및 이의 용도
US20240350614A1 (en) 2021-08-27 2024-10-24 Bioapplications Inc. Vaccine for preventing african swine fever, comprising african swine fever virus-derived antigen protein
KR102726138B1 (ko) 2023-10-17 2024-11-14 대한민국 백시니아 바이러스 재조합 a33r 단백질 및 이를 포함하는 오르소폭스바이러스 항체 진단 키트

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
CA1192510A (en) 1981-05-27 1985-08-27 Lawrence E. Pelcher Rna plant virus vector or portion thereof, a method of construction thereof, and a method of producing a gene derived product therefrom
JPS6054684A (ja) 1983-09-05 1985-03-29 Teijin Ltd 新規ｄνａ及びハイブリツドｄνａ
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
CA1288073C (en) 1985-03-07 1991-08-27 Paul G. Ahlquist Rna transformation vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
GB8608850D0 (en) 1986-04-11 1986-05-14 Diatech Ltd Packaging system
JPS6314693A (ja) 1986-07-04 1988-01-21 Sumitomo Chem Co Ltd 植物ウイルスｒｎａベクタ−
ATE108828T1 (de) 1987-02-09 1994-08-15 Lubrizol Genetics Inc Hybrides rns-virus.
US6846968B1 (en) 1988-02-26 2005-01-25 Large Scale Biology Corporation Production of lysosomal enzymes in plants by transient expression
US5316931A (en) 1988-02-26 1994-05-31 Biosource Genetics Corp. Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes
US5693507A (en) 1988-09-26 1997-12-02 Auburn University Genetic engineering of plant chloroplasts
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5936035A (en) 1988-11-21 1999-08-10 Cohesion Technologies, Inc. Biocompatible adhesive compositions
US5614587A (en) 1988-11-21 1997-03-25 Collagen Corporation Collagen-based bioadhesive compositions
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
DE4009630C2 (de) 1990-03-26 1995-09-28 Reinhard Prof Dr Dr Brossmer CMP-aktivierte fluoreszierende Sialinsäuren sowie Verfahren zu ihrer Herstellung
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
UA48104C2 (uk) 1991-10-04 2002-08-15 Новартіс Аг Фрагмент днк, який містить послідовність,що кодує інсектицидний протеїн, оптимізовану для кукурудзи,фрагмент днк, який забезпечує направлену бажану для серцевини стебла експресію зв'язаного з нею структурного гена в рослині, фрагмент днк, який забезпечує специфічну для пилку експресію зв`язаного з нею структурного гена в рослині, рекомбінантна молекула днк, спосіб одержання оптимізованої для кукурудзи кодуючої послідовності інсектицидного протеїну, спосіб захисту рослин кукурудзи щонайменше від однієї комахи-шкідника
WO1993018148A2 (en) 1992-03-12 1993-09-16 Wisnieski Bernadine J Tumor necrosis factor with modified channel activity
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
CA2144319A1 (en) 1993-07-09 1995-01-19 George N. Cox Recombinant ctla4 polypeptides and methods for making the same
US6329191B1 (en) 1993-08-30 2001-12-11 Hawaii Biotechnology Group, Inc. DNA encoding recombinant coffee bean alpha-galactosidase
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5994086A (en) 1994-03-30 1999-11-30 North Shore University Hospital Method for assessing infertility by binding of mannose to sperm cells
EP0807165A4 (en) 1995-01-30 1998-07-15 New York Blood Center Inc ENZYME -g (a) -GALACTOSIDASE RECOMBINANT
AU7071196A (en) 1995-09-14 1997-04-01 Croptech Development Corporation Production of lysosomal enzymes in plant-based expression systems
US6309646B1 (en) 1996-05-09 2001-10-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
IL119310A (en) 1996-09-26 1999-07-14 Metabogal Ltd Cell/tissue culturing device and method
US20010008766A1 (en) 1998-03-17 2001-07-19 Sylvia Daunert Quantitative binding assays using green fluorescent protein as a label
IL125423A (en) 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
AU7645700A (en) 1999-10-07 2001-05-10 Maxygen Aps Single-chain antagonist polypeptides
US20070172449A1 (en) 2000-03-02 2007-07-26 Xencor, Inc. TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS
US7244823B2 (en) 2000-03-02 2007-07-17 Xencor TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US7687461B2 (en) 2000-03-02 2010-03-30 Xencor, Inc. Treatment of TNF-α related disorders with TNF-α variant proteins
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
BR0116803A (pt) 2001-01-18 2004-02-17 Merck Patent Gmbh Proteìnas de fusão bifuncionais com atividade de glicocerebrosidase
PL369606A1 (en) 2001-10-22 2005-05-02 Applied Research Systems Ars Holding N.V. Gonadotrophins for folliculogenesis
EA007810B1 (ru) 2001-11-16 2007-02-27 Фармекса А/С Иммуногенные миметики мультимерных белков с нерегулярными вставками т-клеточных эпитопов
US20040071686A1 (en) 2002-04-25 2004-04-15 Treco Douglas A. Treatment of alpha-galactosidase A deficiency
CA2427190A1 (en) * 2002-04-30 2003-10-30 Alberta Research Council Inc. Production of recombinant epidermal growth factor in plants
WO2003097791A2 (en) 2002-05-15 2003-11-27 Agricultural Research Organization, The Volcani Center Polynucleotide sequences encoding alkaline a-galactosidases and methods of using same
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
EP1613264A4 (en) 2003-04-16 2007-08-15 Yeda Res & Dev MEDICAMENT FOR THE TREATMENT OF GAUCHER DISEASE AND METHOD FOR IDENTIFYING IT
US7951557B2 (en) * 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
GB2402677A (en) 2003-05-06 2004-12-15 Sirus Pharmaceuticals Ltd Biodegradable polymer
CN101027388A (zh) 2003-06-12 2007-08-29 建新公司 具有增强活性的修饰的人酸性神经磷脂酶及其制备方法
JP2005043317A (ja) 2003-07-25 2005-02-17 Olympus Corp 糖鎖と生体分子との反応を検出する方法
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20070275007A1 (en) 2003-11-05 2007-11-29 The Government Of The United States Of America, Represented By The Secretary Of Health And Human S Carbohydrate Antigen-Nanoparticle Conjugates and Uses Thereof as Antimetastatic Agents in Treating Cancer
WO2005056760A2 (en) 2003-12-03 2005-06-23 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
AU2005211775B2 (en) 2004-02-06 2009-10-08 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
WO2006093524A2 (en) 2004-07-16 2006-09-08 The General Hospital Corporation Antigen-carbohydrate conjugates
WO2006108052A2 (en) 2005-04-06 2006-10-12 Genzyme Corporation Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting
EP2441840B1 (en) 2005-07-18 2017-09-06 Protalix Ltd. Mucosal or enteral administration of biologically active macromolecules
KR20070065157A (ko) 2005-12-19 2007-06-22 이수근 고객맞춤형 투자자산 관리기능을 갖는 인터넷뱅킹 시스템및 방법
ES2569066T3 (es) 2006-07-25 2016-05-06 Lipoxen Technologies Limited Conjugación N-terminal de ácido polisiálico a proteínas
WO2008075957A1 (en) 2006-12-21 2008-06-26 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of fabry disease
PT2121713E (pt) 2007-01-18 2013-06-25 Genzyme Corp Oligossacáridos compreendendo um grupo aminooxi e seus conjugados
EP1955712A1 (en) 2007-02-09 2008-08-13 Scil proteins GmbH Multimeric conjugate
SG187447A1 (en) 2007-05-07 2013-02-28 Protalix Ltd Large scale disposable bioreactor
WO2008157263A2 (en) 2007-06-15 2008-12-24 Arkansas State University Methods of delivery of molecules to cells using a ricin subunit and compositions relating to same
CA2696699A1 (en) 2007-08-20 2009-02-26 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
US20110184293A1 (en) 2008-07-10 2011-07-28 Elisha Rabinovitz Device, method and kit for in vivo detection of a biomarker
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
WO2011061736A1 (en) 2009-11-17 2011-05-26 Protalix Ltd. Alkaline alpha galactosidase for the treatment of fabry disease
WO2011107990A1 (en) * 2010-03-02 2011-09-09 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
EP2542572B1 (en) 2010-03-02 2015-05-06 Protalix Ltd. Multimeric forms of therapeutic proteins and uses thereof
SMT202000201T1 (it) 2011-01-20 2020-05-08 Protalix Ltd Composizioni di alfa-galattosidasi

Also Published As

Publication number Publication date
DK3272861T3 (da) 2020-03-23
WO2012098537A1 (en) 2012-07-26
EP2665814B1 (en) 2017-05-17
JP2014506450A (ja) 2014-03-17
CN103443270A (zh) 2013-12-11
PT3272861T (pt) 2020-03-26
US9732333B2 (en) 2017-08-15
SI3272861T1 (sl) 2020-06-30
LTPA2023531I1 (es) 2023-11-27
CA2824791A1 (en) 2012-07-26
LUC00320I2 (es) 2026-02-02
BR112013018516A2 (pt) 2019-05-21
SMT202000201T1 (it) 2020-05-08
KR101883803B1 (ko) 2018-07-31
CN103443270B (zh) 2017-06-06
AU2011356137A1 (en) 2013-08-15
IL227552A0 (en) 2013-09-30
JP5913372B2 (ja) 2016-04-27
RS60129B1 (sr) 2020-05-29
WO2012098537A8 (en) 2013-08-08
DK2665814T3 (en) 2017-09-11
EP2665814A1 (en) 2013-11-27
BR112013018516B1 (pt) 2023-11-07
EP3272861B1 (en) 2019-12-18
CY1122794T1 (el) 2021-05-05
LT3272861T (lt) 2020-03-25
IL227552B (en) 2018-05-31
LTC3272861I2 (es) 2025-09-10
KR20140015330A (ko) 2014-02-06
US20130295065A1 (en) 2013-11-07
EP3272861A1 (en) 2018-01-24
PL3272861T3 (pl) 2020-07-13

Similar Documents

Publication Publication Date Title
ES2774190T3 (es) Composiciones de alfa-galactosidasa
EA201290567A1 (ru) Получение гетерологичных полипептидов в микроводорослях, внеклеточные микроводорослевые тельца, композиции и способы их получения и применения
MX2013013644A (es) Peptidos de transito al cloroplasto y metodos de uso.
MX354555B (es) Polipeptidos de la hormona de crecimiento y metodos de preparacion y su uso.
BR112012013782A8 (pt) "antagonistas de pcsk9"
EP2553102A4 (en) HIGH PERFORMANCE EXPRESSION OF RECOMBINANT TOXIN PROTEINS
MX2014005108A (es) Constructos de polipeptidos y sus usos.
UA115120C2 (uk) Спосіб застосування химерного поліпептиду фактора ix
HRP20181315T1 (hr) Nove signalne sekvence za poboljšanje ekspresije proteina i izlučivanja rekombinantnih enzima i drugih proteina
PL3756657T3 (pl) Preparaty peptydu n-końcowego aneksyny a1 i sposoby
CL2012002884A1 (es) Polipeptido que comprende un dominio decimo de fibronectina de tipo iii que se unen a la proteina covertasa subtilisina kexina tipo q ( pcsk9); composicion farmacéutica que comprende dicho polipeptido.
AU2013312359A8 (en) Genetically modified non-human animals and methods of use thereof
SG11201503879QA (en) Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
UA115546C2 (uk) Синтетичний транзитний пептид хлоропластів та спосіб його одержання
BR112012015005A2 (pt) Proteínas cry inseticidas cry1ca modificadas
MX2016008355A (es) Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.
MX2013010392A (es) Proteinas de fusion npp1.
MX369726B (es) Polipéptidos con actividad proteasa.
AR132348A2 (es) Polinucleótidos, polipéptidos mejorados de aciltransferasa y sus métodos de uso
EP2576626A4 (en) STABLE, FUNCTIONAL AND CHIMERIC CELL BIOHYDROLASE ENZYMES OF CLASS 1
EP2606121A4 (en) COMPOSITION WITH PERIVASCULAR STEM CELLS AND NELL-1 PROTEIN
WO2010138555A3 (en) Small peptide expression system in mammalian cells
IL236663A0 (en) Production of chaperone proteins secreted from the intra-plasmic reticulum (hr chaperones), human, recombinant, natural, by using their natural sequence markers in yeast expression systems
IN2014MN01562A (es)
IN2014DN09468A (es)